Table 2.

Status of Salmonella Paratyphoid A Vaccines

Vaccine	Description	Vaccine Manufacturer	Clinical Trial Stage	Bivalent Vaccine
Conjugated
O:2-TT	O-specific polysaccharide (O:2) conjugated to tetanus toxoid	Developed by National Institutes of Health, USA Technology transfer to Chengdu and Lanzhou Institutes of Biological Products, China	Phase 2	Intended for a bivalent vaccine O:2,12-TT + Vi-TT
O:2-CRM197	O-specific polysaccharide (O:2) conjugated to carrier protein CRM197, a nontoxic mutant diphtheria toxin	Developed by GSK Vaccines Institute for Global Health Technology transfer to Biological E, Ltd, India	Preclinical	Intended for a bivalent vaccine O:2,12-CRM197 + Vi-CRM197
Live Attenuated
CVD1902	Deletions in guaBA operon and clpX operon of S. Paratyphi A strain ATCC 9150	Developed by University of Maryland Center for Vaccine Development and Global Health (CVD) Licensed to Bharat Biotech International, Ltd, India	Phase 1	Intended for a bivalent vaccine CVD 1902 + CVD 909